
Advanced BioMatrix Acquires HyStem from Lineage Cell Therapeutics
Advanced BioMatrix has acquired the HyStem line of products from Lineage Cell Therapeutics – previously BioTime/ESI Bio/Glycosan. HyStem® kits are based on innovative thiolated hyaluronic acid technology. With HyStem®, researchers can create customizable 3D hydrogels for culturing cells whose natural environment is rich in hyaluronic acid. Read More















